rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TYRA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      How Phase 2 Cancer Trial Data At Tyra Biosciences (TYRA) Has Changed Its Investment Story

      Tyra Biosciences reported a third quarter 2026 net loss of US$51.1 million and a basic loss per share of US$0.74 as spending on three clinical programs for dabogratinib continued. A recent financing round raised about US$400 million and extended funding visibility through 2030. The same update highlighted early Phase 2 SURF302 data for dabogratinib in FGFR3 altered bladder cancer, where a 79% overall response rate and an oral, potentially long term dosing profile could reshape how...

      Nov 12Yahoo FinanceTYRA
      Tyra Biosciences earnings up next following bladder cancer data
      Nov 10Investing.comTYRA
      Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
      Nov 10Yahoo FinanceTYRA
      Tyra Biosciences to Participate in Upcoming Investor Conferences
      Nov 5Yahoo FinanceTYRA
      Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book Value

      Tyra Biosciences has delivered a 54.9% gain over the past 3 years, which means anyone looking at the stock today now has to ask whether that share price is still grounded in the company’s book value. For a business at Tyra Biosciences' stage, where hard assets and the balance sheet carry real weight, that question matters more than ever. The 54.9% return over 3 years puts real pressure on the idea that Tyra Biosciences' current valuation is still anchored to what its balance sheet actually...

      Oct 31Yahoo FinanceTYRA
      Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value

      Tyra Biosciences has delivered a 31.8% gain over the past 3 years, yet the recent pullback in the share price raises a practical question for investors who watch fundamentals closely. Is the current market price meaningfully supported by the company’s book value, or has sentiment moved ahead of what the balance sheet can justify? The stock has returned 31.8% over 3 years, which puts real weight on whether the balance sheet can underpin that kind of share price progress. For a clinical stage...

      Oct 17Yahoo FinanceTYRA
      Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

      Tyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

      Oct 14Yahoo FinanceTYRA
      Tyra Biosciences, Inc. Rings the Opening Bell

      About This EventTyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.

      Oct 13NasdaqTYRA
      Exclusive BAC Article: Tyra Biosciences; Positive Data Dabogratinib LG-IR-NMIBC, Q1 2027 ACH Results Same Drug, Expansion LG-UTUC Data, And Catalysts (NASDAQ:TYRA)
      Oct 6Seeking AlphaTYRA
      Raymond James reiterates Strong Buy on Tyra Biosciences stock
      Oct 6Investing.comTYRARJF
      Raymond James Updates Healthcare Top Picks for October

      Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

      Oct 1Yahoo FinanceTYRA
      Bladder Cancer Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
      Sep 22BarchartTYRA
      H.C. Wainwright cuts Tyra Biosciences price target to $29 on dilution
      Sep 22Investing.comTYRA
      Oppenheimer Adjusts Price Target on Tyra Bioscience to $40 From $50, Keeps Outperform Rating
      Sep 22Yahoo FinanceTYRA
      Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

      Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor. The study enrolled patients with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At the August 31, 2026 cutoff, 14 participants receiving 60 mg once daily had received treatment and completed at least the three-month disease assessment, […]

      Sep 16Yahoo FinanceTYRA
      Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

      Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value. With the stock resetting after mixed bladder cancer drug data and a sizeable equity offering, the question is how closely that current market price lines up with the assets on its balance sheet. Over the past year, Tyra Biosciences has gained about 105.7%, which raises the issue of whether that move...

      Sep 16Yahoo FinanceTYRA
      Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday
      Sep 14BenzingaTYRA
      Why is Tyra Biosciences stock surging today?
      Sep 14Investing.comTYRA
      Tyra Biosciences prices $400 million stock offering
      Sep 14Investing.comTYRA
      Tyra Bioscience Prices $400 Million Offering of Shares and Warrants
      Sep 14Yahoo FinanceTYRA
      Cantor Fitzgerald reiterates Tyra Biosciences stock rating
      Sep 14Investing.comTYRA
      Update: Tyra Bioscience Shares Rise After Pricing $400 Million Offering
      Sep 14Yahoo FinanceTYRA
      Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and Owlet (OWLT)

      Detailed price information for Tyra Biosciences Inc (TYRA-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailTYRAOWLT
      Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data
      Sep 10Investing.comTYRA
      Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow (NASDAQ:TYRA) 2026-09-10
      Sep 10Seeking AlphaTYRA
      Tyra Biosciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: oral drug push
      Sep 9Investing.comTYRA
      Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA)
      Sep 9Seeking AlphaTYRA
      Why Is Tyra Biosciences Stock Sinking Wednesday?
      Sep 9BenzingaTYRA
      Tyra disappoints investors with bladder cancer data

      Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

      Sep 9Yahoo FinanceTYRA
      Why This Biotech Stock Just Plummeted To A 10-Month Low

      Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.

      Sep 9Investor's Business DailyTYRA
      Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
      Sep 9Barron'sTYRA
      Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data

      Tyra Biosciences (NASDAQ:TYRA) shares dropped 30% on Wednesday after the biotechnology company released initial results from its Phase 2 SURF302 trial of dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. At the 60 mg once-daily dose, dabogratinib produced a 79% overall response rate and a 64% complete response rate as the best overall response among patients with single and multiple marker lesions combined.

      Sep 9Yahoo FinanceTYRA
      Why is Tyra Biosciences stock plunging today?
      Sep 9Investing.comTYRA
      Tyra Biosciences stock tumbles 30% on phase 2 trial results
      Sep 9Investing.comTYRA
      Tyra drops after mid-stage trial data for lead asset in bladder cancer
      Sep 9Seeking AlphaTYRA
      Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

      Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibit

      Sep 9Yahoo FinanceTYRA
      Tyra Biosciences to Present at the Cantor Global Healthcare Conference

      Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference:

      Sep 8Yahoo FinanceTYRA
      Piper Sandler reiterates Tyra Biosciences stock rating ahead of data
      Sep 8Investing.comTYRA
      H.C. Wainwright reiterates Tyra Biosciences stock rating at buy
      Sep 8Investing.comTYRA
      Tyra Biosciences: 'Hold' IR-NMIBC Data Sept. 9 With Caution Ahead For 2027 Readouts (TYRA)

      Tyra Biosciences (TYRA) downgraded to Hold ahead of phase 2 SURF302 data; review FGFR3-targeting SNAP platform, cash runway, and key catalysts—read now.

      Sep 6Seeking AlphaTYRA
      Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug
      Sep 4Seeking AlphaTYRA
      Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
      Sep 4MorningstarTYRA
      TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout

      Tyra is set to host a conference call on September 9 to discuss initial results from its Phase 2 study evaluating Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.

      Sep 4Yahoo FinanceTYRA

      This is the newest page. Registered accounts read further back.